1E Therapeutics

About

Funding history · 1 round · $120.0M total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is 1E Therapeutics' primary focus?

1E Therapeutics is a drug-development company creating RNA-targeting therapeutics based on a proprietary drug-design platform.

When was 1E Therapeutics founded?

1E Therapeutics was founded in July 2021.

How much funding has 1E Therapeutics raised in total?

1E Therapeutics has raised a total of $120,000,000.

When did 1E Therapeutics complete its Seed funding round, and who was the lead investor?

In December 2021, 1E Therapeutics completed a Seed funding round of $120,000,000, with Marius Nacht as the lead investor.

Where is 1E Therapeutics headquartered?

1E Therapeutics is headquartered in Rehovot, Israel, at Haim Holtsman Street 7.

What is the current employee count for 1E Therapeutics?

1E Therapeutics currently has 11-50 employees, with an exact count of 45.

What types of indications does 1E Therapeutics' drug development process address?

1E Therapeutics' drug development process addresses chronic life-threatening indications, emerging and evolving pathogens, and has lead compounds for oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.

What is the current product stage of 1E Therapeutics?

1E Therapeutics is currently in the clinical trial product stage.

Sectors & technology

Highlights

Tags